Public Market Listing
2561HKEX
Live quotes, historical charts, and market capitalization for VISEN Pharmaceuticals are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
lonapegsomatropin(Skytrofa) | Approved | Growth hormone receptorProtein / enzyme therapeutic | Growth Hormone Deficiency |
palopegteriparatide(Yorvipath) | Approved | PTH1 receptor (PTH replacement)Peptide | Hypoparathyroidism |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
August 2027 (1)
Est. primary completion 2027-08 · NCT07706764 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
lonapegsomatropin · SkytrofaPhase 3Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Est. primary completion 2028-02 · NCT07221851 · CT.gov ↗
What to watch
September 2028 (1)
Est. primary completion 2028-09 · NCT07924059 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.